- Home
- RFI vs YMAB Comparison
RFI vs YMAB Comparison
Compare RFI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- YMAB
- Stock Information
- Founded
- RFI 1992
- YMAB 2015
- Country
- RFI United States
- YMAB United States
- Employees
- RFI N/A
- YMAB N/A
- Industry
- RFI Investment Managers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- YMAB Health Care
- Exchange
- RFI Nasdaq
- YMAB Nasdaq
- Market Cap
- RFI 323.2M
- YMAB 386.7M
- IPO Year
- RFI N/A
- YMAB 2018
- Fundamental
- Price
- RFI $11.88
- YMAB $8.52
- Analyst Decision
- RFI
- YMAB Buy
- Analyst Count
- RFI 0
- YMAB 11
- Target Price
- RFI N/A
- YMAB $15.02
- AVG Volume (30 Days)
- RFI 69.8K
- YMAB 1.7M
- Earning Date
- RFI 01-01-0001
- YMAB 08-08-2025
- Dividend Yield
- RFI 8.25%
- YMAB N/A
- EPS Growth
- RFI N/A
- YMAB N/A
- EPS
- RFI N/A
- YMAB N/A
- Revenue
- RFI N/A
- YMAB $85,385,000.00
- Revenue This Year
- RFI N/A
- YMAB N/A
- Revenue Next Year
- RFI N/A
- YMAB $15.23
- P/E Ratio
- RFI N/A
- YMAB N/A
- Revenue Growth
- RFI N/A
- YMAB N/A
- 52 Week Low
- RFI $9.62
- YMAB $3.55
- 52 Week High
- RFI $12.52
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- RFI 45.16
- YMAB 81.55
- Support Level
- RFI $11.80
- YMAB $8.50
- Resistance Level
- RFI $12.04
- YMAB $8.53
- Average True Range (ATR)
- RFI 0.10
- YMAB 0.15
- MACD
- RFI -0.01
- YMAB 0.25
- Stochastic Oscillator
- RFI 30.00
- YMAB 99.54
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.